NCT04671901 2025-05-28A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid TumorsMemorial Sloan Kettering Cancer CenterPhase 2 Terminated2 enrolled 4 charts
NCT04478123 2024-02-14Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood CancerMemorial Sloan Kettering Cancer CenterPhase 2 Completed62 enrolled 7 charts
NCT00299182 2021-09-21Study of AMG 531 to Evaluate the Safety & Efficacy in Patients With Non-Hodgkin's LymphomaM.D. Anderson Cancer CenterPhase 1/2 Completed50 enrolled 11 charts
NCT01676961 2018-10-15Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving ChemotherapyNYU Langone HealthPhase 2 Terminated5 enrolled 4 charts
NCT01444417 2017-02-09Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric PatientsAmgenPhase 3 Completed62 enrolled 16 charts 1 FDA
NCT00515203 2014-07-25Safety and Efficacy Study of Romiplostim (AMG 531) to Treat ITP in Pediatric SubjectsAmgenPhase 1/2 Completed22 enrolled 13 charts 1 FDA
NCT00147225 2014-05-08AMG 531 in Patients With Advanced Malignancy Receiving Treatment With CarboplatinM.D. Anderson Cancer CenterPhase 1/2 Completed55 enrolled 11 charts
NCT00413283 2013-10-24Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)AmgenPhase 2 Completed63 enrolled 15 charts
NCT00283439 2011-06-20A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With LymphomaAmgenPhase 1/2 Completed39 enrolled 13 charts